Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 16, 2020 (6 years ago)

Childrens Robitussin Honey Cough and Chest Congestion DM (Dextromethorphan Hbr, Guaifenesin)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Delivery System: the dosing cups are missing graduations applicable to certain age groups.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Childrens Robitussin Honey Cough and Chest Congestion DM, dextromethorphan (cough suppressant), guaifenesin (expectorant), 4 FL OZ. bottle (118 mL), Distributed by: Pfizer, Madison, NJ 07940 USA, UPC: 50300318760128, NDC: 0031-8760-12.

Affected NDC 0031-8760-12

Compare with the code on your package — it is the most precise check available.

Drug: Guaifenesin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Childrens Robitussin Honey Cough and Chest Congestion DM
dextromethorphan HBr, guaifenesin
NDC 00031-8760
DEXTROMETHORPHAN HYDROBROMIDE 10 mg/10mL; GUAIFENESIN 100 mg/10mL Solution
Oral
Haleon US Holdings LLC OTC
Recalling firm
Glaxosmithkline Consumer Healthcare Holdings
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1361-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Guaifenesin recalls

See all
Class III · Low risk

Kids' Cough and Chest Congestion

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Ongoing Failed specification Denison Pharmaceuticals, LLC D-0034-2025

Other recalls by Glaxosmithkline Consumer Healthcare Holdings

All 2020 recalls
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0182-2023
Class I · High risk

Advil (ibuprofen)

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0181-2023
Class II · Moderate risk

TUMS Antacid

Presence of Foreign Substance: The foreign material is primarily comprised of glass mineral wool.

Completed Particulate / foreign matter GlaxoSmithKline Consumer Healthcare Holdings LLC D-0079-2024